TLC599 – 変形性関節症治療薬のパイプライン – 市場インサイトと2032年までの予測

Report Overview

KEY INSIGHTS

TLC599 is a proprietary formulation of dexamethasone sodium phosphate (DSP) utilizing the BioSeizer technology, designed to deliver up to 24 weeks of continuous pain relief. TLC599 offers the benefit of locally delivering a powerful, clinically validated steroid that typically has a short half-life, providing both immediate and sustained effects. This emerging therapy presents several advantages, including rapid pain relief, prolonged maintenance of up to 24 weeks, reduced risk of cartilage damage and toxicity, enhanced drug retention within the joints, and flexible needle size options, making it suitable for use in small joints.

BioSeizer, developed by the Taiwan Liposome Company, is a proprietary technology used in pharmaceutical product development. It utilizes multilayer lipid membranes to encapsulate active therapeutic molecules, ensuring a prolonged duration of drug release.

The BioSeizer nanoparticles are engineered to release their payload steadily as each lipid layer gradually collapses over time, which is particularly advantageous in NSAIDs in osteoarthritis treatment. This technology is adaptable for both small molecules and larger biologics, allowing for extended therapeutic effects, which can be beneficial for osteoarthritis patients seeking longer-lasting relief from osteoarthritis medication.

The drug is developed by the Taiwan Liposome Company, founded in the year 1997 and is headquartered in Taipei City, Taiwan. Taiwan Liposome Company Ltd is a biopharmaceutical firm specializing in drug delivery technology and new drug research. The company focuses on developing lipid-based formulations, parenteral drugs, and various other pharmaceutical products. Additionally, Taiwan Liposome Company provides a range of services related to the advancement of drug delivery technologies and the development of innovative therapeutics.

MARKET POTENTIAL AND POSITIONING

TLC599 is a liposomal formulation of dexamethasone developed for controlled and extended release to manage knee osteoarthritis pain. Unlike conventional intra-articular anti-inflammatory treatments, which can have toxic side effects and damage cartilage proteins, TLC599 offers a novel approach with potentially fewer adverse effects. Currently, in Phase III clinical trials, TLC599 is being evaluated for its safety and effectiveness in treating knee osteoarthritis.

In June 2022, Taiwan Liposome Company (TLC) and Endo International, through its subsidiary Endo Ventures Limited (EVL), formed a partnership. Under this agreement, TLC is responsible for developing TLC599, while EVL will manage regulatory approval and commercialization in the United States.

Upon obtaining regulatory approval, Endo will exclusively manufacture, market, and distribute TLC599 in the United States. This collaboration positions TLC599 as a promising new option in the US market for managing knee osteoarthritis pain, offering a potentially safer and more effective alternative to existing treatments with long-term pain relief benefits.

REGIONAL ANALYSIS

Inkwood Research offers an analysis of eight key markets:

• United States
• Germany
• France

o France’s healthcare landscape is characterized by a robust and well-developed system that combines public and private sectors. These investments are directed toward improving patient outcomes, managing chronic diseases, and supporting advanced therapeutic research, including regenerative medicine and innovative drug development.

o Osteoarthritis is a major public health concern in France, affecting millions of people, particularly among the elderly population. As the population ages, the prevalence of osteoarthritis is expected to rise, driving demand for new and effective treatment options.

• United Kingdom
• Italy
• Spain
• Canada
• Korea

Table of Contents

1. INTRODUCTION TO THE REPORT
2. TLC599 OVERVIEW
2.1. PRODUCT DETAIL
2.2. CLINICAL DEVELOPMENT
2.2.1. CLINICAL STUDIES
2.2.2. CLINICAL TRIALS INFORMATION
2.2.3. SAFETY AND EFFICACY
2.3. OTHER DEVELOPMENTAL ACTIVITIES
2.4. PRODUCT PROFILE
3. COMPETITIVE LANDSCAPE
3.1. MARKETED THERAPIES
3.2. LATE-STAGE EMERGING THERAPIES
4. TLC599 MARKET ASSESSMENT
4.1. MARKET OUTLOOK OF TLC599 IN OSTEOARTHRITIS
5. 8 MAJOR MARKET’S ANALYSIS
5.1. MARKET SIZE OF TLC599 IN THE 8 MAJOR MARKETS FOR OSTEOARTHRITIS
5.2. 8 COUNTRY ANALYSIS
5.2.1. MARKET SIZE OF TLC599 IN UNITED STATES FOR OSTEOARTHRITIS
5.2.2. MARKET SIZE OF TLC599 IN GERMANY FOR OSTEOARTHRITIS
5.2.3. MARKET SIZE OF TLC599 IN FRANCE FOR OSTEOARTHRITIS
5.2.4. MARKET SIZE OF TLC599 IN ITALY FOR OSTEOARTHRITIS
5.2.5. MARKET SIZE OF TLC599 IN SPAIN FOR OSTEOARTHRITIS
5.2.6. MARKET SIZE OF TLC599 IN UNITED KINGDOM FOR OSTEOARTHRITIS
5.2.7. MARKET SIZE OF TLC599 IN CANADA FOR OSTEOARTHRITIS
5.2.8. MARKET SIZE OF TLC599 IN KOREA FOR OSTEOARTHRITIS
6. SWOT ANALYSIS
7. ANALYST PERSPECTIVE

List of Tables

LIST OF TABLES
TABLE 1: TLC599, CLINICAL TRIAL DESCRIPTION, 2023
TABLE 2: TLC599, GENERAL DESCRIPTION
TABLE 3: MARKETED THERAPIES
TABLE 4: EMERGING THERAPIES
TABLE 5: TLC599 MARKET SIZE IN THE 8 MAJOR MARKETS, IN $ MILLION (2019–2032)
TABLE 6: TLC599 MARKET SIZE IN UNITED STATES, IN $ MILLION (2019–2032)
TABLE 7: TLC599 MARKET SIZE IN GERMANY, IN $ MILLION (2019–2032)
TABLE 8: TLC599 MARKET SIZE IN FRANCE, IN $ MILLION (2019–2032)
TABLE 9: TLC599 MARKET SIZE IN ITALY, IN $ MILLION (2019–2032)
TABLE 10: TLC599 MARKET SIZE IN SPAIN, IN $ MILLION (2019–2032)
TABLE 11: TLC599 MARKET SIZE IN UNITED KINGDOM, IN $ MILLION (2019–2032)
TABLE 12: TLC599 MARKET SIZE IN CANADA, IN $ MILLION (2019–2032)
TABLE 13: TLC599 MARKET SIZE IN KOREA, IN $ MILLION (2019–2032)

List of Figures

LIST OF FIGURES
FIGURE 1: TLC599 MARKET SIZE IN THE 8 MAJOR MARKETS, IN $ MILLION (2019–2032)
FIGURE 2: TLC599 MARKET SIZE IN UNITED STATES, IN $ MILLION (2019–2032)
FIGURE 3: TLC599 MARKET SIZE IN GERMANY, IN $ MILLION (2019–2032)
FIGURE 4: TLC599 MARKET SIZE IN FRANCE, IN $ MILLION (2019–2032)
FIGURE 5: TLC599 MARKET SIZE IN ITALY, IN $ MILLION (2019–2032)
FIGURE 6: TLC599 MARKET SIZE IN SPAIN, IN $ MILLION (2019–2032)
FIGURE 7: TLC599 MARKET SIZE IN UNITED KINGDOM, IN $ MILLION (2019–2032)
FIGURE 8: TLC599 MARKET SIZE IN CANADA, IN $ MILLION (2019–2032)
FIGURE 9: TLC599 MARKET SIZE IN KOREA, IN $ MILLION (2019–2032)

Inkwood Researchは広範な市場を対象にし、また主要地域/国別の市場調査レポートで世界中の企業に活用されているインドに本社をおく市場調査会社です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

世界市場レポート

地域別レポート

国別レポート

ご購入に関するご案内

価格・納期について

• 価格
  • 2023年7月より全レポートの価格が値上げされました。弊社ウェブサイトでは旧価格が掲載されているページもございますが、2023年6月以前に出版されたレポートにも値上げが適用されます。予めご了承ください。
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
    • 印刷不可設定のPDFです。
  • コーポレートライセンス
    • 同一企業および関連会社間人数無制限でレポートファイルをご共有可能です。
    • PDF（印刷可能）とExcelをご提供いたします。
• 納期
  • ご注文後3-4営業日以内

• 納品形態
  • Eメール

注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでのご注文をお待ちしております。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

Inkwood Research出版の市場調査レポートに関するご質問やサンプルページのご依頼等はいつでもお気軽にお問合せください。

Inkwood Research 出版レポート一覧